Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about

< Previous 1 2 3 4 5 Next >
Top Trending Stocks to Consider On Monday, June 6
From ACCESSWIRE
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations 
From GlobeNewswire News Releases
Cyclacel Announces Reverse Stock Split
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for... 
From GlobeNewswire News Releases
Cyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally... 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for... 
From GlobeNewswire News Releases
Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
Preclinical Data Presented at the AACR 2016 Meeting 
From GlobeNewswire News Releases
Cyclacel Announces Receipt of Nasdaq Extension
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); (“Cyclacel” or the “Company”) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control... 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Shareholder Alert: Investigation of Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/30/2016 -- An investigation for shareholders in Cyclacel Pharmaceuticals Inc was announced over potential breaches of fiduciary duties by certain directors at Cyclacel... 
From SBWire - Latest Press Releases
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results
-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT -- 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Cyclacel Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc. (NasdaqCM: CYCC) concerning possible breaches of fiduciary duty by the board of directors of the company.... 
From Business Wire News Releases
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (“Cyclacel” or the “Company”) today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff... 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the... 
From GlobeNewswire News Releases
Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016
Company to Present at the Biotech Showcase(TM) 2016 Conference 
From GlobeNewswire News Releases
Molecular Basis for Development of Cyclacel’s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation of preclinical data demonstrating the molecular basis for the development of... 
From GlobeNewswire News Releases
CYC065, Cyclacel’s Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models
In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results
Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST 
From GlobeNewswire News Releases
Mechanistic Rationale for CYC065, Cyclacel’s CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
CYC065 Predicted to be Effective in Leukemia and Triple Negative Breast Cancer 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for... 
From GlobeNewswire News Releases
Data to be Presented on CYC065, Cyclacel’s CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
Mechanistic Rationale of CYC065 in Targeted Solid Tumors and Hematology 
From GlobeNewswire News Releases
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the... 
From GlobeNewswire News Releases
Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), today announced the presentation of preclinical data demonstrating the molecular rationale for the clinical... 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
Conference Call Scheduled August 11, 2015 at 4:30 p.m. EDT 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results
From GlobeNewswire News Releases
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
From PR Newswire
First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
- Unique Dual Action Through Inhibition of Cyclin E and ACTH Production in Pituitary Tumors - 
From GlobeNewswire News Releases
Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis
Novel CDK Inhibitor-Based Approach to Treat Cystic Fibrosis 
From GlobeNewswire News Releases
Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.